Shares of Decoy Therapeutics shifted sharply higher Tuesday, climbing 9.7% to $1.13, after the micro-cap biotech released a third-quarter update touting once-weekly dosing potential for its lead pan-coronavirus drug candidate and a planned regulatory filing in the second half of 2027. Decoy Therapeutics Touts Once-Weekly Dosing Breakthrough, but With $8 Million and a Ticking Clock, Can It Reach the Clinic Before the Money Runs Out

Shares of Decoy Therapeutics jumped 9.7% to $1.13 Tuesday morning after the Cambridge-based biotech released a third-quarter update announcing that its lead antiviral — designed to protect high-risk patients from all coronaviruses — showed potential for once-weekly dosing in preclinical studies, compared to daily dosing for earlier versions. The company also set a target: file a Clinical Trial Application or Investigational New Drug application in the second half of 2027 to begin a Phase 1 trial. The question for investors is whether the story can survive the math.

  • Once-Weekly Dosing Sounds Good, but It's Still in Animals. Less frequent dosing could improve adherence in high-risk patients and lower the company's cost of goods. That matters because the target population — immunocompromised patients, transplant recipients, people with chronic lung disease — needs treatments they'll actually take. There are currently no approved therapies for endemic human coronaviruses, giving Decoy a genuine unmet-need argument. But the data is preclinical, meaning it has only been tested in lab animals, not humans. The jump from weekly animal dosing to a viable human drug is long and littered with failures.

  • The Cash Covers Months, Not Years. Decoy reported $8.1 million on the balance sheet at September 30, 2026. Meanwhile, the company is burning over $2.6 million in operating cash per quarter, which gives it roughly three quarters of runway — well short of the second-half 2027 filing target. That gap virtually guarantees Decoy will need to raise more money, likely by selling new shares, which dilutes (shrinks) existing shareholders' ownership stakes.

  • A Recent History of Near-Delisting Adds Risk. Decoy executed a 1-for-12 reverse stock split in March 2026 to stay listed on Nasdaq after its share price spent 30 consecutive days below $1.00. The company remains under a Mandatory Panel Monitor until March 31, 2027, meaning any renewed breach could trigger automatic delisting. At $1.13, there is almost no margin for error.

  • Gates Foundation Backing Adds Credibility, Not Cash Flow. The program is partially funded by the Gates Foundation, and Decoy has met with U.S. government and military agencies and is applying for several non-dilutive funding opportunities.

The company is also evaluating manufacturing locations and talking to makers of pulmonary delivery systems. These are promising signals, but none has yet produced committed capital large enough to bridge the funding gap.

The bottom line: Decoy is chasing a real medical need in a coronavirus treatment market valued at roughly $17.8 billion in 2026. But with a sub-$1 million market capitalization, a listing on life support, and a cash pile that won't last to the filing date, shareholders are betting the science will attract funding before the runway ends.